Navigation Links
Anesiva Announces Pivotal Phase 3 Trial of Zingo(TM) Meets Primary Endpoint and Significantly Reduces Venous Access Pain in Adults
Date:10/16/2007

Company Plans to File Supplemental New Drug Application with FDA in First

Quarter 2008

SOUTH SAN FRANCISCO, Calif., Oct. 16 /PRNewswire-FirstCall/ -- Anesiva, Inc. (Nasdaq: ANSV) today announced positive top-line results from its pivotal Phase 3 trial. The multi-center, randomized, double-blind study with 699 adult patients met its primary endpoint, demonstrating less venous procedural pain in those treated with Zingo(TM) (lidocaine hydrochloride monohydrate) powder intradermal injection system compared to placebo (p= 0.003). Patients received Zingo or placebo one to three minutes prior to undergoing venous access procedures (IV insertions or blood draws). Zingo was found to be well tolerated in this patient population. Anesiva plans to file a supplemental new drug application (sNDA) with the U.S. Food and Drug Administration (FDA) in the first quarter of 2008 for the use of Zingo in adults.

"We've now shown that Zingo works in both the pediatric and adult populations. An expanded label from the FDA to include adults could greatly expand the market opportunity for us," said John P. McLaughlin, chief executive officer of Anesiva. "We have a world-class commercialization team that has significant efforts underway to prime the market for Zingo's introduction to pediatric hospitals in order to prepare for a strong launch and the development of a very successful business."

Zingo is already approved by the FDA to provide local analgesia prior to venipuncture or peripheral intravenous cannulation in children three to 18 years of age. Its onset of action is one to three minutes. Venous access procedures are among the most common procedures performed at a hospital, with more th
'/>"/>

SOURCE Anesiva, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Anesiva Announces Phase 2 Data Showing Substantial, Long-Term Pain Reductions with Adlea(TM) (formerly 4975) in Osteoarthritis of the Knee
2. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
3. Sygnis Pharma AG announces date for presentation of clinical results
4. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
6. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
7. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
11. Protox Announces Positive Clinical Data from Prostate Cancer Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2008)...RIAS HR Pilot Study Compares Genous, Boston Scient...her Presentations Focus on Real-World Use of Genou...e Who Could Not Tolerate Dual-Antiplatelet ..., May 15 /- OrbusNeich today announce...ymposium at EuroPCR 2008,support the use of the co...
(Date:5/15/2008)...is., May 15 /- Omega 3 fatty acids bo...ered as a credible natural,alternative and may hav...s,recent in vivo French study reveals. While seve...ega-3 in hyperactivity, French researchers have,hy...ositive effects on,impulse control., These resear...
(Date:5/14/2008)...ass., May 14 /- Biopure Cor... results from its Phase II coronary,revascularizat...,EuroIntervention Journal. The paper is entitled "...ed oxygen therapeutics in elective percutaneous,co...gn, and haemodynamic,results." The manuscript was ...
(Date:5/14/2008)... experts to be important for cervical cancer preve...l/ -- New data from an,extended follow-up study sh...cer candidate vaccine, CERVARIX(R) generates susta...t the two most common cervical cancer-causing,huma...s the longest,duration of sustained neutralizing a...
Breaking Medicine Technology:Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 2Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 3Multiple Clinical Data Presentations at EuroPCR 2008 Support Use of OrbusNeich's Genous(TM) Bio-engineered R stent(TM) as Safe Alternative to Drug-Eluting Stents 4Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 2Biopure Announces Publication of Phase II Proof-of-Concept Coronary Trial 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 2CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 3CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 4CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 5CERVARIX(R) Shown to Provide Longest Duration of Sustained Neutralizing Antibodies to Date 6Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution 1599 1Perrigo Company Announces FDA Approval for Ciclopirox Topical Solution 1599 2Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 692 1Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 692 2Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 692 3Arpida Presents Preclinical and Clinical Data on Iclaprim at ICAAC 692 4New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 328 1New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 328 2New Topical Therapy Safely Treats Serious Skin Infections Without Systemic Side Effects 328 3New Data Show That GlaxoSmithKlines Rotarix 28R 29 Could Be Given With Other Routine Infant Vaccines in the U S 325 1New Data Show That GlaxoSmithKlines Rotarix 28R 29 Could Be Given With Other Routine Infant Vaccines in the U S 325 2New Data Show That GlaxoSmithKlines Rotarix 28R 29 Could Be Given With Other Routine Infant Vaccines in the U S 325 3New Data Show That GlaxoSmithKlines Rotarix 28R 29 Could Be Given With Other Routine Infant Vaccines in the U S 325 4New Data Show That GlaxoSmithKlines Rotarix 28R 29 Could Be Given With Other Routine Infant Vaccines in the U S 325 5
...0, 2007 - Valeant,Pharmaceuticals International (N...2 data for retigabine, a first-in-class,neuronal p...ndependent, scientific journal. The authors conclu...rated reduction in monthly,seizure rates in this s...TORE2) are currently underway to further investiga...
...2007 - The two most,prevalent forms of genetic men... share a common cause, according to researchers at...em, a crippled,communication network in the brain,... genetics of the disorders are very different, the...id Daniel Madison,PhD, associate professor of mol...
Other Medicine Technology:Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 2Valeant Pharmaceuticals Announces Publication of Retigabine Phase 2,Study Data in Neurology 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 2Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 3Fragile X, Down Syndromes Linked to Faulty Brain Communication,Stanford Researcher Finds 4
(Date:5/16/2008)...eficiency were more likely to suffer recurrence, d...thDay News) -- Women with breast cancer who have a... more likely to have a recurrence or to die from t...y, the researchers also found that only 24 percent...when they were diagnosed. , "This study found t...
(Date:5/16/2008)... Calif., May 16 /PRNewswire-FirstCall/ -- Anesiva,.... McLaughlin, the company,s,chief executive office...obal Healthcare Conference in New York City on May...ebcast or the subsequent archived recording, log o... page, and click on Events.,Please connect to Anes...
(Date:5/15/2008)..., illness, violence and other problems that can un...to experience temporary separations from one or bo...rgarten. Published in the May/June issue of Ambul... Rochester, New York, warns that such kids are at ...these separations are good predictors of which chi...
(Date:5/15/2008)...5 /Xinhua-PRNewswire-FirstCall/ -- China Yingxia,I...ina Yingxia" or "the,Company"), a leading provider...lopment, manufacture and distribution of organic n...l care products in the People,s Republic,of China ...the first,quarter ended March 31, 2008., First ...
Breaking Medicine News(10 mins):Health News:Low Levels of Vitamin D Spell Trouble for Breast Cancer Patients 2Health News:Low Levels of Vitamin D Spell Trouble for Breast Cancer Patients 3Health News:Separation from mom, dad linked with learning trouble in kids 2Health News:Separation from mom, dad linked with learning trouble in kids 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 2Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 3Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 4Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 5Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 6Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 7Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 8Health News:China Yingxia International, Inc. Reports First Quarter 2008 Results 9
...r may delay your chances of getting treated// for ...he British Journal of Cancer, valuable time is los...nosis gets delayed. Patients with suspected prosta...es later than those with breast cancer patients wh...
...hed the association between adult urinary incontin...more than 1000 Turkish women, the research says th... the same for exhibiting lack of control in contro...rs feel that these women may suffer from some faul...
...first direct association of faulty metabolism with...rallels from an animal study. Atherosclerosis or c... substances, cholesterol, cellular waste products,...r lining of the arteries. This build up is called ...
...tsburgh had said in a new study that there’s adequ...ith age, in spite of the elderly frequenting the b...dder capacity and stability, urethral closure pres...ontraction strength from 95 females of ages 22 to ...
Other Medicine News:
... Novametrix' family of capnography products. Along...handheld, mainstream capnographs available today, ...rway condition and ventilatory status. Based on th...iniaturized the size, not the performance. TIDAL W...
The Models 512 and 513 handheld pulse oximeters incorporate "digital signal processing. This advanced technology is able to process pulsatile signals at much higher resolutions and speeds of 100 time
...ulse Oximeter is a one-of-a-kind oximeter that off...tion of the N-20PA has been shock-tested, vibratio... conditions it has even withstood the rigors of M... check measurements and also useful for continuous...
...er with Oxismart XL Advanced Signal Processing rea...through nonspecific noise to find the pulse and tr... N395 monitor is also equipped with SatSeconds Ala...mable alarm sensitivity for pulse oximetry. SatSec...
Medicine Products: